Pfizer and Allergan--which both confirmed on Thursday that they're in "friendly" deal talks--may be intrigued with the prospect of a tie-up. But politicians gung-ho about stopping tax inversions? Not so much.
Mylan has swept aside one of the legal hurdles set up by Perrigo, which has been fighting on two continents to try to derail Mylan's takeover of the generics competitor.
Baxter had scarcely completed its July separation from therapeutics business Baxalta when it suddenly became a target for activist investor Third Point in early August. Last month, Baxter offered an olive branch to the hedge fund by adding two new directors to its board, one of them from the firm.
Pfizer--searching for deals in advance of a potential split-up later this decade--has approached Allergan about an acquisition, Allergan said in a statement on Thursday. The drugmakers are in "preliminary friendly discussions," Allergan said, though they won't necessarily amount to a combination.
The Wall Street Journal broke the news last night that Pfizer and Allergan have had some early discussions about merging into a $330 billion behemoth. Neither company is talking, but the irresistible conclusion remains that a deal just might make sense.
Diabetes testing company Nipro Diagnostics is selling out to China's Sinocare for $273 million, cashing in on a rapidly growing Chinese diagnostics market while charting plans for international expansion.
A proposed merger of Endologix and TriVascular Technologies is designed to create an abdominal aortic aneurysm powerhouse. But Wall Street wasn't convinced, causing Endologix shares to plunge by more than 25% in early trading.
Perrigo has railed repeatedly against Mylan's hostile takeover bid and introduced massive cost-cuts and streamlining efforts to try to keep its shareholders loyal. Its next step in fending off its unwanted suitor? Heading to Israel.
Royal Philips has hit a regulatory stumbling block with the $3.3 billion sale of 80% of its combined Lumileds and automotive lighting businesses, which it has already separated out as discontinued operations on its balance sheet. Philips also hasn't yet sorted out its strategic plans for its remaining Lighting business, which it said it will separate out during the first half of 2016.
Amid a recent flurry of healthcare company consolidations, buyouts and sales this year, interest in snapping up Unilabs is heating up following last month's news that the Swiss diagnostics company was for sale.